Market Cap
$848.5K
SC
SCLXW
Scilex Holding Co
—
Market cap$848.5K
High Impact Filing (8/10) Biotech & Drug Discovery
Snapshot
The big-picture read on SCLXW right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
2 funds
Inst. Value
$394.00
Inst. Activity
1 buys / 0 sells
SEC Reports
5
Price chart 30d -23.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jul 6, 2026 other
Jun 2, 2026 SEC Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Compan
Scilex Holding Company filed an S-3 shelf registration to register up to 2,083,067 primary shares issuable upon exercise
S-3 — Impact 6/10
Scilex Holding Co's Form S-3 shelf registration (File No. 333-295109) was declared effective by the SEC on May 22, 2026.
EFFECT — Impact 6/10
Scilex's indirect subsidiary ACEA Therapeutics agreed to sell 100% of ACEA Pharma to Phoenix Asia Holdings in exchange f
8-K — Impact 8/10
Dec 31, 2025 Inst.
BANK OF AMERICA CORP — ADD
265 shares ($25.00)
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 1 bullish, 2 bearish, 1 mixed, 1 neutral · avg impact 6.0/10.
BEARISHS-36/10
Scilex Holding Company filed an S-3 shelf registration to register up to 2,083,067 primary shares is
Jun 2, 2026
BEARISHEFFECT6/10
Scilex Holding Co's Form S-3 shelf registration (File No. 333-295109) was declared effective by the
May 26, 2026
BULLISH8-K8/10
Scilex's indirect subsidiary ACEA Therapeutics agreed to sell 100% of ACEA Pharma to Phoenix Asia Ho
May 5, 2026
MIXED8-K6/10
Scilex Holding Co entered a binding term sheet to contribute $120 million to Datavault AI Inc. for b
Apr 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Jul 6, 2026
other
Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generati
Jun 16, 2026
other
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026
PALO ALTO, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generati
Jun 12, 2026
activist
Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
PALO ALTO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-gen
Jun 4, 2026
dividend
Scilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
PALO ALTO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-gen
May 22, 2026
dividend
Scilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026
PALO ALTO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-gene
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Institutional ownership
Which big funds own SCLXW (from quarterly 13F filings) and who is adding or trimming.
2 institutional holders with $394.00 total value (3,035 shares) as of 2026-Q2. Top holders: Clear, UBS.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Clear Street Group Inc. | 2,880 | $374.00 | 94.9% | — |
| UBS Group AG | 155 | $20.00 | 5.1% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 165 | 265 | +60.6% | $25.00 |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SCLXW.
Shares short
171,290
Settlement Sep 15, 2026
Change vs prior
-3.4%
Semi-monthly cycle
Days to cover
35.5
At avg daily volume
Of shares outstanding
≈2.0%
Estimate — not % of float
All SCLXW filing & press-release reports (5)
- S-3 reportJun 2, 2026
- EFFECT reportMay 26, 2026
- 8-K reportMay 5, 2026
- 8-K reportApr 28, 2026
- S-3 reportApr 16, 2026